Abstract 2056P
Background
The wider availability of oncological treatment and the improved survival of cancer patients have increased the frequency of emergency consultations and their impact on healthcare. The aim of this study was to investigate the variables that influence hospital admission, re-consultation and clinical outcomes among oncology patients who seek emergency care.
Methods
Single-center, observational and prospective study. We analyzed a sample of 554 oncology patients who consulted in the Emergency Deparment during regular office hours between March-22 and March-23. Statistics: Chi-squared test to assess association between variables. Kaplan-Meier curves and log-rank test for survival analysis. Significance level: p-value <=0.05.
Results
The baseline characteristics of the study participants were: 50.2% females, 21.5% lung cancer, 68.8% stage IV, 25.8% consulted for digestive symptoms, 37% were hospitalized and 16.4% reconsulted in the following 15 days. The overall median survival was 54 weeks. Factors that were associated with a higher likelihood of hospitalization were lung cancer (26.9% of admissions), stage IV (80.7%), monotherapy chemotherapy (CT) (36.3%), first-line treatment for metastatic disease (40.9%), ECOG 2 (36.8%), digestive symptoms as reason for consultation (29.2%) and complications secondary to the tumor itself as definitive diagnosis (32.2%). Factors significantly associated with a higher likelihood of reconsultation within the following 15 days were lung cancer (19.3% of reconsultations), monotherapy CT (38.6%), ECOG 1 (42.1%) and infectious pathology and complications secondary to the tumor itself (28.1% each one). Factors significantly associated with lower overall survival were hospital admission (median: 16 weeks, 95% CI 3.7-28.2), diagnosis of complications secondary to the tumor itself (median: 11 weeks, 95% CI 10.3 - 23.6) and reconsultation (median: 17 weeks, 95% CI 10.3-23.6).
Conclusions
Among oncology patients admitted to the Emergency department, complications secondary to the underlying oncological disease represent the most relevant variable in the field of oncological emergencies due to their impact on the likelihood of hospitalization, reconsultation and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Sanofi, Lundbeck, Angelini. M.A. Ivars: Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06